Category:A61P35/00
- A61P35/00 - Antineoplastic Agents
A61P35/00 is an IPC (International Patent Classification) code that falls under the broader category of A61P, which is focused on specific therapeutic activity of chemical compounds or medicinal preparations. Specifically, A61P35/00 pertains to antineoplastic agents, which are used in the treatment of neoplastic diseases, commonly known as cancer. These agents are central to oncology, a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
- Key Elements of A61P35/00
1. **Antineoplastic Agents**: This class includes drugs and substances that inhibit or prevent the growth and spread of tumors or malignant cells. They are often referred to as chemotherapy drugs.
2. **Treatment of Neoplastic Diseases**: The primary focus of these agents is the treatment of various forms of cancer, including solid tumors and hematological cancers.
3. **Chemical Compounds and Preparations**: The category includes a wide range of chemical compounds and formulations, each designed to target specific types of cancer cells or mechanisms of tumor growth and metastasis.
4. **Innovation in Oncology**: The field of antineoplastic agents is a rapidly evolving area of medicine, with continuous research and development leading to new and more effective treatments, including targeted therapies and immunotherapies.
- Relevant Companies and Innovations
Several pharmaceutical and biotechnology companies are at the forefront of research and development in this area. These companies are involved in the discovery and production of new antineoplastic agents, aiming to improve cancer treatment outcomes.
1. **Large Pharma Companies**: Well-known companies like Pfizer, Roche, and Novartis have extensive portfolios of antineoplastic agents and are continually researching new drugs.
2. **Biotech Firms**: Smaller, specialized biotech firms are also significant players in this field, often focusing on novel approaches like targeted therapy and personalized medicine.
3. **Startups and Emerging Companies**: A number of startups are pushing the boundaries in this field, focusing on innovative approaches like gene therapy and novel drug delivery systems.
- IPC Classification and Links
- A61P35/00 is a subclassification within the A61P category, which covers therapeutic activity of chemical compounds or medicinal preparations. - For more detailed information about related classifications, see A61P35/00.
- Categories
- -
- Conclusion
A61P35/00 represents a crucial and dynamic field in medical research and pharmaceutical development. It's an area characterized by significant innovation and advancement, with a direct impact on cancer treatment and patient outcomes.
Pages in category "A61P35/00"
The following 57 pages are in this category, out of 57 total.
1
- 17767856. ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS simplified abstract (Arizona Board of Regents on Behalf of Arizona State University)
- 17768199. Proteasome Inhibitors simplified abstract (Mayo Foundation for Medical Education and Research)
- 18208490. LUTEINIZING HORMONE RECEPTOR BINDING AGENTS AND LUTEINIZING HORMONE AGONISTS TO IDENTIFY, EXPAND, ABLATE AND MODIFY STEM CELLS simplified abstract (Fred Hutchinson Cancer Center)
- 18234229. METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS simplified abstract (DANA-FARBER CANCER INSTITUTE, INC.)
- 18250727. SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 18274307. Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277) simplified abstract (The Regents of the University of California)
- 18274979. IMMUNE RECEPTORS WITH SYNTHETIC CO-STIMULATORY DOMAINS simplified abstract (The Regents of the University of California)
- 18279004. LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS simplified abstract (OHIO STATE INNOVATION FOUNDATION)
- 18295214. SELECTIVE MCL-1 BINDING PEPTIDES simplified abstract (Massachusetts Institute of Technology)
- 18302738. METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY simplified abstract (The Regents of the University of California)
- 18314445. ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER simplified abstract (Vanderbilt University)
- 18392493. LUTEINIZING HORMONE-RELEASING HORMONE RECEPTOR (LHRH-R) CONJUGATES AND USES THEREOF simplified abstract (PURDUE RESEARCH FOUNDATION)
- 18461820. MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors simplified abstract (DANA-FARBER CANCER INSTITUTE, INC.)
- 18476573. COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING ALTERNATING ELECTRIC FIELDS AND APOPTOTIC CANCER CELL VACCINATION simplified abstract (Novocure GmbH)
- 18480038. ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER simplified abstract (Arizona Board of Regents on Behalf of Arizona State University)
- 18503556. COMPOUNDS AND METHODS FOR TREATING CANCER simplified abstract (DANA-FARBER CANCER INSTITUTE, INC.)
- 18517327. BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE simplified abstract (Genentech, Inc.)
- 18546081. MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN ROR1 simplified abstract (The Regents of the University of California)
- 18550914. METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS simplified abstract (The General Hospital Corporation)
- 18551314. USE OF OXYMETHYL-MODIFIED DERIVATIVE OF QUERCETIN IN PREPARATION OF DRUG FOR INHIBITING TUMOR CELL PROLIFERATION simplified abstract (ZHEJIANG UNIVERSITY)
- 18552478. ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES simplified abstract (The Board of Trustees of the Leland Stanford Junior University)
2
- 20240010655. DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND simplified abstract (IMPACT THERAPEUTICS (SHANGHAI), INC)
- 20240010980. NATURAL KILLER CELLS WITH ENHANCED ACTIVITY simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
- 20240016787. METHODS FOR TREATMENT OF CANCER AND PHAGOCYTOSIS-DEFICIENCY RELATED DISEASES simplified abstract (RDiscovery, LLC)
- 20240018130. Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine simplified abstract (Zhejiang Hisun Pharmaceutical Co., Ltd.)
- 20240018157. CYCLIC COMPOUNDS AND METHODS OF USING SAME simplified abstract (Schrödinger, Inc.)
- 20240024436. METHOD FOR TREATING CANCER simplified abstract (CHILDREN'S MEDICAL CENTER CORPORATION)
- 20240024473. HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE simplified abstract (Purdue Research Foundation)
- 20240026028. ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF simplified abstract (JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.)
- 20240033363. ALC1 Inhibitors and Synergy with PARPi simplified abstract (Eisbach Bio GmbH)
- 20240043445. Thienopyranones and Furanopyranones as Kinase, Bromodomain, and Checkpoint Inhibitors simplified abstract (SignalRx Pharmaceuticals, Inc.)
- 20240050439. 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES simplified abstract (Spring Bioscience AB)
- 20240051938. SELECTIVE BRD4-DEGRADER MOLECULES simplified abstract (REGENTS OF THE UNIVERSITY OF MINNESOTA)
- 20240051948. ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE simplified abstract (Petra Pharma Corporation)
B
- Blockchain patent applications on 22nd Mar 2024
- Blockchain patent applications on April 11th, 2024
- Blockchain patent applications on April 18th, 2024
- Blockchain patent applications on April 4th, 2024
- Blockchain patent applications on February 15th, 2024
- Blockchain patent applications on February 1st, 2024
- Blockchain patent applications on February 22nd, 2024
- Blockchain patent applications on February 29th, 2024
- Blockchain patent applications on February 8th, 2024
- Blockchain patent applications on January 11th, 2024
- Blockchain patent applications on January 18th, 2024
- Blockchain patent applications on January 25th, 2024
- Blockchain patent applications on March 14th, 2024
- Blockchain patent applications on March 21st, 2024
- Blockchain patent applications on March 28th, 2024
- Blockchain patent applications on May 16th, 2024
F
U
- US Patent Application 17815514. ANTI-CD46 ANTIBODIES AND METHODS OF USE simplified abstract
- US Patent Application 18032932. ATTENUATED CANCER CELLS AND METHODS RELATED THERETO simplified abstract
- US Patent Application 18248291. TRANSCRIPTION ACTIVE COMPLEX TARGETING CANCER DRUG FROM VIRAL PROTEIN SEQUENCE simplified abstract